NCT02991612 (RFXM) is a NA clinical trial of Rifaximin in Cirrhosis, sponsored by Shanghai Zhongshan Hospital.

Who is sponsoring NCT02991612?

NCT02991612 is sponsored by Shanghai Zhongshan Hospital.

What drugs are being tested in NCT02991612?

Interventions in NCT02991612: Rifaximin.

What condition does NCT02991612 study?

NCT02991612 studies Cirrhosis, Esophageal and Gastric Varices, Gastrointestinal Hemorrhage.

Is NCT02991612 still recruiting?

NCT02991612 is currently completed. Last updated 11 May 2018.

Last reviewed 2018-05-11 · How we verify

NCT02991612: RFXM

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Rifaximin in Patients With Gastroesophageal Variceal Bleeding

Completed NA Last updated 11 May 2018

What this trial tests

NA trial testing Rifaximin in Cirrhosis in 80 participants. Completed in 28 February 2018.

Timeline

25 November 2016

Primary endpoint
22 December 2017

28 February 2018

Quick facts

Lead sponsor	Shanghai Zhongshan Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	80
Start date	25 November 2016
Primary completion	22 December 2017
Estimated completion	28 February 2018
Sites	1 location across China

Drugs / interventions tested

Rifaximin (rifaximin) — full drug profile →

Conditions studied

Cirrhosis — all drugs for Cirrhosis →
Esophageal and Gastric Varices — all drugs for Esophageal and Gastric Varices →
Gastrointestinal Hemorrhage — all drugs for Gastrointestinal Hemorrhage →

Sponsor

Shanghai Zhongshan Hospital

Who can join

Adults 18 to 75, any sex, with Cirrhosis or Esophageal and Gastric Varices. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to evaluate the safety and efficacy of Rifaximin in the treatment of cirrhotic gastroesophageal variceal bleeding.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis.
Zacharias HD, Kamel F, Kamel F, Tan J, et al · · 2023 · cited 22× · PMID 37467180 · DOI 10.1002/14651858.cd011585.pub2
Impact of rifaximin on cirrhosis complications and gastric microbiota in patients with gastroesophageal variceal bleeding: A pilot randomized controlled trial.
Huang XQ, Ai YJ, Li F, Ye ST, et al · · 2024 · cited 1× · PMID 39443081 · DOI 10.1111/1751-2980.13314

Verify or expand the search:

Other trials of Rifaximin

Trials testing the same drug.

NCT07209371 — Rifaximin Versus No Intervention for the Treatment of IgA Monoclonal Gammopathy of Undetermined Significance · Phase 2 · recruiting
NCT07203846 — Modulation of Gut MicroFLORA With Rifaximin to Reduce High Platelet Reactivity in Post-ACS Patients on Ticagrelor · Phase 4 · not yet recruiting
NCT06483737 — Human Albumin Infusion in Liver Cirrhosis and Overt Hepatic Encephalopathy (HACHE) · NA · recruiting
NCT06808009 — Goal Directed Ammonia Lowering Therapy in Hyperammonemic ACLF Patients With no Overt HE to Reduce Major Adverse Liver Re · NA · not yet recruiting
NCT06652087 — Rifaximin and Cardiac Function in Patients with Heart Failure with Preserved Ejection Fraction · NA · recruiting

Other recruiting trials for Cirrhosis

Currently open trials in the same condition.

NCT07322237 — DICE Study- Diastolic Improvement With Carvedilol & Empagliflozin in Patients With Cirrhosis · Phase 4 · recruiting
NCT07521332 — Apixaban-PK Trial: Preventing Portal Hypertension Complications in Cirrhosis · Phase 4 · recruiting
NCT07461545 — Efficacy of Apixaban in the Treatment of Portal Vein Thrombosis Occurring More Than One Year After LS · NA · recruiting
NCT07461532 — Efficacy of Apixaban in Treating Portal Vein Thrombosis Occurring More Than One Year After LSD · NA · recruiting
NCT07462091 — Vagus Nerve-guided Laparoscopic Splenectomy and Azygoportal Disconnection · NA · recruiting

Other Shanghai Zhongshan Hospital trials

Trials by the same sponsor.

NCT07353476 — Radiotherapy Plus Anti-PD-1 Versus Anti-PD-1 Alone in ypTanyN⁺M0 NSCLC · Phase 2 · not yet recruiting
NCT07508956 — Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric · Phase 3 · not yet recruiting
NCT07535632 — SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cance · Phase 2 · not yet recruiting
NCT07531368 — BBAP With CS Mapping Guidance · NA · not yet recruiting
NCT07501104 — Neoadjuvant Pucotenlimab Combined With Lenvatinib and Temozolomide in Resectable Stage IIB/III Acral Melanoma · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02991612 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Zhongshan Hospital
Last refreshed: 11 May 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02991612.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing